Trials / Completed

CompletedNCT00630630

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 3 (actual)

Sponsor: UCB Pharma · Industry
Sex: Female
Age: 18 Years – 45 Years
Healthy volunteers: Not accepted

Summary

The relationship between hormone cycling/fluctuations and the occurrence of seizures in women has received considerable discussion in the medical literature. This study investigated the efficacy and tolerability of LEV treatment for subjects with catamenial exacerbation of partial onset seizures.

Conditions

Epilepsy

Interventions

Type	Name	Description
DRUG	Levetiracetam
OTHER	Placebo

Timeline

Start date: 2002-11-01
Primary completion: 2003-11-01
Completion: 2003-11-01
First posted: 2008-03-07
Last updated: 2013-11-26

Source: ClinicalTrials.gov record NCT00630630. Inclusion in this directory is not an endorsement.